DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency. Export

@article{citeulike:5983057, abstract = {Previous studies have shown that blocking DLL4 signaling reduced tumor growth by disrupting productive angiogenesis. We developed selective anti-human and anti-mouse DLL4 antibodies to dissect the mechanisms involved by analyzing the contributions of selectively targeting DLL4 in the tumor or in the host vasculature and stroma in xenograft models derived from primary human tumors. We found that each antibody inhibited tumor growth and that the combination of the two antibodies was more effective than either alone. Treatment with anti-human DLL4 inhibited the expression of Notch target genes and reduced proliferation of tumor cells. Furthermore, we found that specifically inhibiting human DLL4 in the tumor, either alone or in combination with the chemotherapeutic agent irinotecan, reduced cancer stem cell frequency, as shown by flow cytometric and in vivo tumorigenicity studies.}, author = {Hoey, Timothy and Yen, Wan-Ching C. and Axelrod, Fumiko and Basi, Jesspreet and Donigian, Lucas and Dylla, Scott and Fitch-Bruhns, Maureen and Lazetic, Sasha and Park, In-Kyung K. and Sato, Aaron and Satyal, Sanjeev and Wang, Xinhao and Clarke, Michael F. and Lewicki, John and Gurney, Austin}, citeulike-article-id = {5983057}, citeulike-linkout-0 = {http://dx.doi.org/10.1016/j.stem.2009.05.019}, citeulike-linkout-1 = {http://view.ncbi.nlm.nih.gov/pubmed/19664991}, citeulike-linkout-2 = {http://www.hubmed.org/display.cgi?uids=19664991}, citeulike-linkout-3 = {http://f1000biology.com/guardpages/evaluation/1166172//article/article.asp}, citeulike-linkout-4 = {http://scholar.google.com/scholar?cluster=14481474283915852650}, day = {7}, doi = {10.1016/j.stem.2009.05.019}, issn = {1875-9777}, journal = {Cell stem cell}, keywords = {anti-cancer, anti-csc}, month = {August}, number = {2}, pages = {168--177}, posted-at = {2009-10-21 21:14:56}, priority = {2}, title = {DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency.}, url = {http://dx.doi.org/10.1016/j.stem.2009.05.019}, volume = {5}, year = {2009} }

TY - JOUR ID - citeulike:5983057 L3 - citeulike-article-id:5983057 N2 - Previous studies have shown that blocking DLL4 signaling reduced tumor growth by disrupting productive angiogenesis. We developed selective anti-human and anti-mouse DLL4 antibodies to dissect the mechanisms involved by analyzing the contributions of selectively targeting DLL4 in the tumor or in the host vasculature and stroma in xenograft models derived from primary human tumors. We found that each antibody inhibited tumor growth and that the combination of the two antibodies was more effective than either alone. Treatment with anti-human DLL4 inhibited the expression of Notch target genes and reduced proliferation of tumor cells. Furthermore, we found that specifically inhibiting human DLL4 in the tumor, either alone or in combination with the chemotherapeutic agent irinotecan, reduced cancer stem cell frequency, as shown by flow cytometric and in vivo tumorigenicity studies. IS - 2 JF - Cell stem cell SN - 1875-9777 EP - 177 TI - DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency. VL - 5 SP - 168 KW - anti-cancer KW - anti-csc AU - Hoey, Timothy AU - Yen, Wan-Ching AU - Axelrod, Fumiko AU - Basi, Jesspreet AU - Donigian, Lucas AU - Dylla, Scott AU - Fitch-Bruhns, Maureen AU - Lazetic, Sasha AU - Park, In-Kyung AU - Sato, Aaron AU - Satyal, Sanjeev AU - Wang, Xinhao AU - Clarke, Michael AU - Lewicki, John AU - Gurney, Austin PY - 2009/08/07/ UR - http://dx.doi.org/10.1016/j.stem.2009.05.019 ER -